Phase
Condition
Lung Disease
Cystic Fibrosis
Scar Tissue
Treatment
N/AClinical Study ID
Ages > 6 All Genders
Study Summary
Eligibility Criteria
Inclusion
Key Inclusion Criteria:
Ability to provide written informed consent (parental/guardian consent and participantassent if less than [<] 18 years of age).
Evidence of completed participation in the double-blind study, PTC124-GD-009-CF (Study 009).
Body weight greater than or equal to (≥) 16 kilograms (kg).
Performance of a valid, reproducible spirometry test using the study-specificspirometer during the screening period.
Confirmed laboratory values within the central laboratory ranges at screening.
In male and female participants who are sexually active, willingness to abstain fromsexual intercourse or employ a barrier or medical method of contraception during thestudy drug administration and 60-day follow-up period.
Willingness and ability to comply with all study procedures and assessments, includingscheduled visits, drug administration plan, laboratory tests, and study restrictions.
Exclusion
Key Exclusion Criteria:
Chronic use of systemic tobramycin within 4 weeks prior to screening.
Evidence of pulmonary exacerbation or acute upper or lower respiratory tract infection (including viral illnesses) within 3 weeks prior to screening or between screening andrandomization.
Any change (initiation, change in type of drug, dose modification, schedulemodification, interruption, discontinuation, or re-initiation) in a chronictreatment/prophylaxis regimen for CF or for CF-related conditions within 4 weeks priorto screening and randomization.
Known hypersensitivity to any of the ingredients or excipients of the study drug.
Exposure to another investigational drug within 4 weeks prior to screening.
Treatment with intravenous antibiotics within 3 weeks prior to screening.
History of solid organ or hematological transplantation.
Ongoing immunosuppressive therapy (other than corticosteroids).
Positive hepatitis B surface antigen, hepatitis C antibody test or humanimmunodeficiency virus (HIV) test.
Known portal hypertension.
Pregnancy or breast-feeding.
Study Design
Connect with a study center
Hôpital Universitaire des Enfants Reine Fabiola
Brussels,
BelgiumSite Not Available
University Hospital Brussels
Brussels,
BelgiumSite Not Available
University Hospital Leuven
Leuven,
BelgiumSite Not Available
Hôpital Necker - Enfants Malades
Paris,
FranceSite Not Available
Hôpital des Enfants
Toulouse, 31059
FranceSite Not Available
Klinikum der Universität Köln
Köln,
GermanySite Not Available
Hadassah University Hospital - Mount Scopus
Jerusalem, 91240
IsraelSite Not Available
Università La Sapienza
Roma,
ItalySite Not Available
Azienda Ospedaliera di Verona
Verona,
ItalySite Not Available
Hospital Universitario La Paz
Madrid,
SpainSite Not Available
Karolinska University Hospital, Huddinge
Stockholm,
SwedenSite Not Available
University of Alabama-Birmingham
Birmingham, Alabama 35233
United StatesSite Not Available
Miller Children's Hospital Long Beach
Long Beach, California 90806
United StatesSite Not Available
Denver Children's Hospital
Aurora, Colorado 80045
United StatesSite Not Available
Children's Hospital Chicago
Chicago, Illinois 60614
United StatesSite Not Available
Children's Hospital Boston
Boston, Massachusetts 02115
United StatesSite Not Available
Beth Israel Medical Center
New York, New York 10003
United StatesSite Not Available
Beth Israel Medical Center
New York City, New York 10003
United StatesSite Not Available
Rainbow Babies & Children's Hospital
Cleveland, Ohio 44106
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.